PRESS ROOM

AhR Pharmaceuticals Receives a Federal Grant (Nov. 2nd, 2010)

Madison, Wisconsin, USA. November 2nd, 2010.

The AhR Pharmaceuticals, Inc., a pharmaceutical R & D company based in Madison, Wisconsin, USA, received a grant from the Qualifying Therapeutic Discovery Project Program co-administered by the US Internal Revenue Services (IRS) and Department of Health and Human Services (HHS). The project, which was evaluated by the US Department of HHS as to "show significant potential to produce new and cost-saving therapies, support jobs and increase U.S. competitiveness", is entitled "Development of ITE into an Efficacious and Sustainable but Low Side-effect Therapeutic Agent in Combating Cancer".

"It feels fairly good," said Dr. Jiasheng (Jason) Song, the VP and Chief Scientific Officer of the AhR Pharmaceuticals, "to be recognized and supported by the federal agencies." "Even though most of our costs for drug development were paid by our strategic partner and therefore the costs directly from our company were minimum, so was the dollar value of the grant," Dr. Song continued, "we do value and appreciate the support from IRS and HHS."

Please follow this link to IRS website to learn more about the program. To find all the Wisconsin technology companies which received the grants, please click here. To read a related news story from the Wisconsin State Journal, please follow this link.

The AhR Pharmaceuticals is currently focusing on the development of a newly discovered natural hormone named ITE into an efficacious and sustainable but low side-effect therapeutic agent in combating cancer, obesity, and diseases related to imbalanced actions of immune systems. 

AhR Pharmaceuticals Announces the Demonstration of ITE Efficacy in Cancer Therapy (July 15th, 2009)

Madison, Wisconsin, USA. July 15th, 2009.

The AhR Pharmaceuticals, Inc., a pharmaceutical R & D company based in Madison, Wisconsin, USA, announced today that the efficacy of ITE cancer therapy had been demonstrated at a whole animal level. "This is a direct, real-world, and in vivo proof that the concept works," explained Dr. Jiasheng (Jason) Song, VP and Chief Scientific Officer of the AhR Pharmaceuticals. "Previously, what we had was theoretic analysis on the multiple therapeutic potentials of the natural hormone ITE. Now, we have the direct proof." "This is an extremely important milestone reached," said Dr. Song.

ITE is a natural hormone, endogenous ligand, or physiological ligand for a receptor named aryl hydrocarbon receptor. ITE was identified by Dr. Jiasheng (Jason) Song, Dr. Hector F. DeLuca, and their colleagues when they were working in the Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USA.

The AhR Pharmaceuticals is currently focusing on the development of a newly discovered natural hormone named ITE into an efficacious and sustainable but low side-effect therapeutic agent in combating cancer, obesity, and other disorders.

Please contact us if you have any question, comment, or suggestion. We are looking forward to hearing from you.